A promising diabetes drug treatment could reach stage three clinical trials this year. Glenmark Pharmaceuticals claimed this week that their experimental new diabetes treatment molecule, known as meloglipti, will reach last-stage clinical trials by the end of 2009.
Glycaemic control amongst patients with type 2 diabetes mellitus has been proved efficient at phase IIb level clinical trials. The company used a 12-week study of 494 patients. The results showed low incidences of hypoglycaemia and a neutral influence on body weight .
Glenmark, who are based in Mumbai, India, will continue to look for partners with whom to outlicence the product. The company ended a deal with Merck last year, as the German pharmaceutical giant exits diabetes research .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…